Hormone Therapy

Top Story

Endocrine Society: Insurers must cover transgender therapies

Endocrine Society: Insurers must cover transgender therapies
September 15, 2017

The Endocrine Society released a new clinical practice guideline this week outlining recommended care for transgender individuals, along with a position statement calling on federal and private insurers to cover such interventions as prescribed by a physician.

The guideline, published online in the Journal of Clinical Endocrinology & Metabolism, makes several new recommendations not advocated in past guidelines, including a suggestion that clinicians begin hormone suppression for transgender adolescents who meet diagnostic criteria for gender dysphoria once they exhibit the first physical changes of puberty. The guideline does not recommend gender-affirming hormone treatment for pre-pubertal children.

Transgender military ban prompts discussion on treatment costs, burden

Endocrine Today, September 2017
The decision by President Donald Trump to reinstitute a ban on transgender adults serving in the U.S. military, citing “tremendous medical costs,” has…
In the Journals Plus

Oral contraceptive plus spironolactone safely addresses androgen excess in PCOS

September 14, 2017
Women with polycystic ovary syndrome treated with a combination oral contraceptive with spironolactone were not at increased risk for metabolic or cardiovascular…
In the Journals PlusPerspective

Hormone therapy does not increase mortality risk in postmenopausal women

September 12, 2017
All-cause mortality and death rates from cardiovascular diseases, cancer and other causes do not significantly differ among women assigned to receive hormone therapy for…
More Headlines »

Practical Lipidology® Volume 4, Number 1: Focus on LDL Reduction and PCSK9 Inhibition

This activity is supported by an educational grant from Amgen

A preponderance of data shows that low-density lipoprotein cholesterol (LDL-C) plays a causal role in atherosclerotic…
More »
Meeting News Coverage

Vlog: Global endocrinology community gathers for ICE/ENDO 2014

June 21, 2014
More »
Resource Centers

What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia and…
More »